drugset / Trial / NCT05021900
Efficacy and Safety of Tenalisib (RP6530), in Patients With Locally Advanced or Metastatic Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
Phase II, randomized, open-label study, designed to evaluate the preliminary efficacy and safety of tenalisib at two dose levels in 40 patients with locally advanced or metastatic breast cancer.
Timeline
- Start
- 2021-10-13
- Primary completion
- 2023-03-31
- Completion
- 2023-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tenalisib | Small molecule | 800 mg | Oral |
| Subject | Tenalisib | Small molecule | 1200 mg | Oral |